PLoS ONE (Jan 2021)

Polycystin-1 is required for insulin-like growth factor 1-induced cardiomyocyte hypertrophy.

  • Carolina Fernández,
  • Natalia Torrealba,
  • Francisco Altamirano,
  • Valeria Garrido-Moreno,
  • César Vásquez-Trincado,
  • Raúl Flores-Vergara,
  • Camila López-Crisosto,
  • María Paz Ocaranza,
  • Mario Chiong,
  • Zully Pedrozo,
  • Sergio Lavandero

DOI
https://doi.org/10.1371/journal.pone.0255452
Journal volume & issue
Vol. 16, no. 8
p. e0255452

Abstract

Read online

Cardiac hypertrophy is the result of responses to various physiological or pathological stimuli. Recently, we showed that polycystin-1 participates in cardiomyocyte hypertrophy elicited by pressure overload and mechanical stress. Interestingly, polycystin-1 knockdown does not affect phenylephrine-induced cardiomyocyte hypertrophy, suggesting that the effects of polycystin-1 are stimulus-dependent. In this study, we aimed to identify the role of polycystin-1 in insulin-like growth factor-1 (IGF-1) signaling in cardiomyocytes. Polycystin-1 knockdown completely blunted IGF-1-induced cardiomyocyte hypertrophy. We then investigated the molecular mechanism underlying this result. We found that polycystin-1 silencing impaired the activation of the IGF-1 receptor, Akt, and ERK1/2 elicited by IGF-1. Remarkably, IGF-1-induced IGF-1 receptor, Akt, and ERK1/2 phosphorylations were restored when protein tyrosine phosphatase 1B was inhibited, suggesting that polycystin-1 knockdown deregulates this phosphatase in cardiomyocytes. Moreover, protein tyrosine phosphatase 1B inhibition also restored IGF-1-dependent cardiomyocyte hypertrophy in polycystin-1-deficient cells. Our findings provide the first evidence that polycystin-1 regulates IGF-1-induced cardiomyocyte hypertrophy through a mechanism involving protein tyrosine phosphatase 1B.